Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:21 PM
Ignite Modification Date:
2025-12-24 @ 10:21 PM
NCT ID:
NCT01557335
Eligibility Criteria:
Inclusion Criteria:
* Male or non-lactating, non-pregnant female subjects who are 40 years or older at the time of initial dosing
--Physical status within normal limits for age and consistent with observations at Screening
* Able to understand and comply with study procedures required and able and willing to provide written informed consent prior to any study procedures being performed
Exclusion Criteria:
* History of hypersensitivity, allergy or intolerance to omeprazole or other proton-pump inhibitors (PPIs)
* History of hypersensitivity, allergy or intolerance to aspirin or any NSAID and/or a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps
* History of hypersensitivity or intolerance to clopidogrel
* History of hepatitis B or C, a positive test for hepatitis B surface antigen, hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or demonstration of HIV antibodies
* History of malignancy, treated or untreated, within the past five years, with the exception of successfully treated basal cell or squamous cell carcinoma of -Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the Investigator's opinion, would endanger a subject if he/she were to participate in the study
* Presence of an uncontrolled acute, or a chronic medical illness, e.g., GI disorder, diabetes, hypertension, thyroid disorder, bleeding disorder, infection, which in the Investigator's opinion would endanger a subject if he/she were to participate in the study or interfere with the objective of this study
* Schizophrenia or bipolar disorder
* GI disorder or surgery leading to impaired drug absorption
* \< 70% platelet aggregation at Screening
* Donation of blood or plasma within 4 weeks of the study
* PPI use or any enzyme inducing/inhibiting agents within 4 weeks prior to dosing
* Taking any antiplatelet drug within 2 weeks of the screening visit or during the study, or more than two 325 mg doses of aspirin or more than 2 doses of any other NSAIDs within 14 days prior to the screening visit
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
40 Years
Study:
NCT01557335
Study Brief:
Protocol Section:
NCT01557335